Effect of food, type of food, and time of food intake on deferasirox bioavailability

Recommendations for an optimal deferasirox administration regimen

Renzo Galanello, Antonio Piga, Maria Domenica Cappellini, Gian Luca Forni, Antonella Zappu, Raffaella Origa, Catherine Dutreix, Rossella Belleli, John M. Ford, Gilles Jacques Rivière, Sébastien Balez, Daniele Alberti, Romain Séchaud

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Deferasirox (ICL670) is representative of a new class of tridentate iron chelators, formulated as tablets for dispersion. Deferasirox has exhibited high potency and a clinically manageable safety profile in preclinical models and in an extensive clinical program. The effect of food and time of food intake on the pharmacokinetics of deferasirox was investigated in healthy volunteers and patients with transfusional hemosiderosis. The bioequivalence of a single oral dose of deferasirox (20 mg/kg) was assessed following administration either before a high-fat or standard breakfast or concurrent with a standard breakfast in comparison with fasted conditions in healthy volunteers. The bioavailability of deferasirox was determined following a single oral dose (20 mg/kg) under fed and fasted conditions in patients. These data show that the type of food, caloric content, and fat content of the meal influence the bioavailability of deferasirox when consumed concomitantly. In contrast, this is not the case when deferasirox is administered at least 30 minutes before a meal. In conclusion, it is recommended that deferasirox be administered at least 30 minutes prior to meals. When this is not feasible, deferasirox should be administered consistently at the same time before meals to limit the sources of variability that affect absorption.

Original languageEnglish
Pages (from-to)428-435
Number of pages8
JournalJournal of Clinical Pharmacology
Volume48
Issue number4
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Biological Availability
Eating
Food
Meals
Breakfast
Healthy Volunteers
Fats
deferasirox
Hemosiderosis
Therapeutic Equivalency
Chelating Agents
Tablets
Iron
Pharmacokinetics
Safety

Keywords

  • Bioavailability
  • Chelation
  • Deferasirox
  • Exjade
  • Food effect
  • ICL670
  • Intake time
  • Iron overload

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of food, type of food, and time of food intake on deferasirox bioavailability : Recommendations for an optimal deferasirox administration regimen. / Galanello, Renzo; Piga, Antonio; Domenica Cappellini, Maria; Luca Forni, Gian; Zappu, Antonella; Origa, Raffaella; Dutreix, Catherine; Belleli, Rossella; Ford, John M.; Rivière, Gilles Jacques; Balez, Sébastien; Alberti, Daniele; Séchaud, Romain.

In: Journal of Clinical Pharmacology, Vol. 48, No. 4, 04.2008, p. 428-435.

Research output: Contribution to journalArticle

Galanello, R, Piga, A, Domenica Cappellini, M, Luca Forni, G, Zappu, A, Origa, R, Dutreix, C, Belleli, R, Ford, JM, Rivière, GJ, Balez, S, Alberti, D & Séchaud, R 2008, 'Effect of food, type of food, and time of food intake on deferasirox bioavailability: Recommendations for an optimal deferasirox administration regimen', Journal of Clinical Pharmacology, vol. 48, no. 4, pp. 428-435. https://doi.org/10.1177/0091270007313327
Galanello, Renzo ; Piga, Antonio ; Domenica Cappellini, Maria ; Luca Forni, Gian ; Zappu, Antonella ; Origa, Raffaella ; Dutreix, Catherine ; Belleli, Rossella ; Ford, John M. ; Rivière, Gilles Jacques ; Balez, Sébastien ; Alberti, Daniele ; Séchaud, Romain. / Effect of food, type of food, and time of food intake on deferasirox bioavailability : Recommendations for an optimal deferasirox administration regimen. In: Journal of Clinical Pharmacology. 2008 ; Vol. 48, No. 4. pp. 428-435.
@article{7490e68e49bf4019a7f49457d026531d,
title = "Effect of food, type of food, and time of food intake on deferasirox bioavailability: Recommendations for an optimal deferasirox administration regimen",
abstract = "Deferasirox (ICL670) is representative of a new class of tridentate iron chelators, formulated as tablets for dispersion. Deferasirox has exhibited high potency and a clinically manageable safety profile in preclinical models and in an extensive clinical program. The effect of food and time of food intake on the pharmacokinetics of deferasirox was investigated in healthy volunteers and patients with transfusional hemosiderosis. The bioequivalence of a single oral dose of deferasirox (20 mg/kg) was assessed following administration either before a high-fat or standard breakfast or concurrent with a standard breakfast in comparison with fasted conditions in healthy volunteers. The bioavailability of deferasirox was determined following a single oral dose (20 mg/kg) under fed and fasted conditions in patients. These data show that the type of food, caloric content, and fat content of the meal influence the bioavailability of deferasirox when consumed concomitantly. In contrast, this is not the case when deferasirox is administered at least 30 minutes before a meal. In conclusion, it is recommended that deferasirox be administered at least 30 minutes prior to meals. When this is not feasible, deferasirox should be administered consistently at the same time before meals to limit the sources of variability that affect absorption.",
keywords = "Bioavailability, Chelation, Deferasirox, Exjade, Food effect, ICL670, Intake time, Iron overload",
author = "Renzo Galanello and Antonio Piga and {Domenica Cappellini}, Maria and {Luca Forni}, Gian and Antonella Zappu and Raffaella Origa and Catherine Dutreix and Rossella Belleli and Ford, {John M.} and Rivi{\`e}re, {Gilles Jacques} and S{\'e}bastien Balez and Daniele Alberti and Romain S{\'e}chaud",
year = "2008",
month = "4",
doi = "10.1177/0091270007313327",
language = "English",
volume = "48",
pages = "428--435",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of food, type of food, and time of food intake on deferasirox bioavailability

T2 - Recommendations for an optimal deferasirox administration regimen

AU - Galanello, Renzo

AU - Piga, Antonio

AU - Domenica Cappellini, Maria

AU - Luca Forni, Gian

AU - Zappu, Antonella

AU - Origa, Raffaella

AU - Dutreix, Catherine

AU - Belleli, Rossella

AU - Ford, John M.

AU - Rivière, Gilles Jacques

AU - Balez, Sébastien

AU - Alberti, Daniele

AU - Séchaud, Romain

PY - 2008/4

Y1 - 2008/4

N2 - Deferasirox (ICL670) is representative of a new class of tridentate iron chelators, formulated as tablets for dispersion. Deferasirox has exhibited high potency and a clinically manageable safety profile in preclinical models and in an extensive clinical program. The effect of food and time of food intake on the pharmacokinetics of deferasirox was investigated in healthy volunteers and patients with transfusional hemosiderosis. The bioequivalence of a single oral dose of deferasirox (20 mg/kg) was assessed following administration either before a high-fat or standard breakfast or concurrent with a standard breakfast in comparison with fasted conditions in healthy volunteers. The bioavailability of deferasirox was determined following a single oral dose (20 mg/kg) under fed and fasted conditions in patients. These data show that the type of food, caloric content, and fat content of the meal influence the bioavailability of deferasirox when consumed concomitantly. In contrast, this is not the case when deferasirox is administered at least 30 minutes before a meal. In conclusion, it is recommended that deferasirox be administered at least 30 minutes prior to meals. When this is not feasible, deferasirox should be administered consistently at the same time before meals to limit the sources of variability that affect absorption.

AB - Deferasirox (ICL670) is representative of a new class of tridentate iron chelators, formulated as tablets for dispersion. Deferasirox has exhibited high potency and a clinically manageable safety profile in preclinical models and in an extensive clinical program. The effect of food and time of food intake on the pharmacokinetics of deferasirox was investigated in healthy volunteers and patients with transfusional hemosiderosis. The bioequivalence of a single oral dose of deferasirox (20 mg/kg) was assessed following administration either before a high-fat or standard breakfast or concurrent with a standard breakfast in comparison with fasted conditions in healthy volunteers. The bioavailability of deferasirox was determined following a single oral dose (20 mg/kg) under fed and fasted conditions in patients. These data show that the type of food, caloric content, and fat content of the meal influence the bioavailability of deferasirox when consumed concomitantly. In contrast, this is not the case when deferasirox is administered at least 30 minutes before a meal. In conclusion, it is recommended that deferasirox be administered at least 30 minutes prior to meals. When this is not feasible, deferasirox should be administered consistently at the same time before meals to limit the sources of variability that affect absorption.

KW - Bioavailability

KW - Chelation

KW - Deferasirox

KW - Exjade

KW - Food effect

KW - ICL670

KW - Intake time

KW - Iron overload

UR - http://www.scopus.com/inward/record.url?scp=40749152342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749152342&partnerID=8YFLogxK

U2 - 10.1177/0091270007313327

DO - 10.1177/0091270007313327

M3 - Article

VL - 48

SP - 428

EP - 435

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -